Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1331–1334. doi: 10.1128/aac.40.6.1331

Didanosine measurement by radioimmunoassay.

M DeRemer 1, R D'Ambrosio 1, G D Morse 1
PMCID: PMC163325  PMID: 8725995

Abstract

Didanosine is commonly prescribed as monotherapy or as part of a combination regimen for patients with human immunodeficiency virus infection. The use of lower doses, either as part of a combination regimen or as a result of dose reduction secondary to clinical intolerance, requires that a sensitive assay method be available for either traditional or population-based pharmacokinetic evaluations. We evaluated a radioimmunoassay technique with a standard curve range of 0 to 100 ng/ml in human plasma, urine, and cerebrospinal fluid and assessed its accuracy and precision for use in pharmacokinetic studies.

Full Text

The Full Text of this article is available as a PDF (243.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balis F. M., Pizzo P. A., Butler K. M., Hawkins M. E., Brouwers P., Husson R. N., Jacobsen F., Blaney S. M., Gress J., Jarosinski P. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis. 1992 Jan;165(1):99–104. doi: 10.1093/infdis/165.1.99. [DOI] [PubMed] [Google Scholar]
  2. Barry M., Howe J. L., Ormesher S., Back D. J., Breckenridge A. M., Bergin C., Mulcahy F., Beeching N., Nye F. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol. 1994 May;37(5):421–426. doi: 10.1111/j.1365-2125.1994.tb05708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collier A. C., Coombs R. W., Fischl M. A., Skolnik P. R., Northfelt D., Boutin P., Hooper C. J., Kaplan L. D., Volberding P. A., Davis L. G. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15;119(8):786–793. doi: 10.7326/0003-4819-119-8-199310150-00003. [DOI] [PubMed] [Google Scholar]
  4. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  5. Drusano G. L., Yuen G. J., Morse G., Cooley T. P., Seidlin M., Lambert J. S., Liebman H. A., Valentine F. T., Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. Antimicrob Agents Chemother. 1992 Jun;36(6):1280–1283. doi: 10.1128/aac.36.6.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Grasela T. H., Walawander C. A., Beltangady M., Knupp C. A., Martin R. R., Dunkle L. M., Barbhaiya R. H., Pittman K. A., Dolin R., Valentine F. T. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine. J Infect Dis. 1994 Jun;169(6):1250–1255. doi: 10.1093/infdis/169.6.1250. [DOI] [PubMed] [Google Scholar]
  7. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
  8. Knupp C. A., Shyu W. C., Dolin R., Valentine F. T., McLaren C., Martin R. R., Pittman K. A., Barbhaiya R. H. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther. 1991 May;49(5):523–535. doi: 10.1038/clpt.1991.63. [DOI] [PubMed] [Google Scholar]
  9. Knupp C. A., Stancato F. A., Papp E. A., Barbhaiya R. H. Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1990 Nov 30;533:282–290. doi: 10.1016/s0378-4347(00)82215-x. [DOI] [PubMed] [Google Scholar]
  10. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  11. Mueller B. U., Pizzo P. A., Farley M., Husson R. N., Goldsmith J., Kovacs A., Woods L., Ono J., Church J. A., Brouwers P. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr. 1994 Jul;125(1):142–146. doi: 10.1016/s0022-3476(94)70141-5. [DOI] [PubMed] [Google Scholar]
  12. Shelton M. J., O'Donnell A. M., Morse G. D. Didanosine. Ann Pharmacother. 1992 May;26(5):660–670. doi: 10.1177/106002809202600511. [DOI] [PubMed] [Google Scholar]
  13. Yarchoan R., Lietzau J. A., Nguyen B. Y., Brawley O. W., Pluda J. M., Saville M. W., Wyvill K. M., Steinberg S. M., Agbaria R., Mitsuya H. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis. 1994 Jan;169(1):9–17. doi: 10.1093/infdis/169.1.9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES